Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer

PURPOSE: To assess whether the combination of letrozole, metronomic cyclophosphamide and sorafenib (LCS) is well tolerated and shows activity in primary breast cancer (BC). METHODS: Thirteen oestrogen receptor-positive, postmenopausal, T2-4, N0-1 BC patients received the LCS combination for 6 months...

Descripción completa

Detalles Bibliográficos
Autores principales: Bazzola, L, Foroni, C, Andreis, D, Zanoni, V, R Cappelletti, M, Allevi, G, Aguggini, S, Strina, C, Milani, M, Venturini, S, Ferrozzi, F, Giardini, R, Bertoni, R, Turley, H, Gatter, K, Petronini, P G, Fox, S B, Harris, A L, Martinotti, M, Berruti, A, Bottini, A, Reynolds, A R, Generali, D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453610/
https://www.ncbi.nlm.nih.gov/pubmed/25461806
http://dx.doi.org/10.1038/bjc.2014.563

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453610/
https://www.ncbi.nlm.nih.gov/pubmed/25461806
http://dx.doi.org/10.1038/bjc.2014.563

Ejemplares similares